JP2009511426A5 - - Google Patents

Download PDF

Info

Publication number
JP2009511426A5
JP2009511426A5 JP2008529121A JP2008529121A JP2009511426A5 JP 2009511426 A5 JP2009511426 A5 JP 2009511426A5 JP 2008529121 A JP2008529121 A JP 2008529121A JP 2008529121 A JP2008529121 A JP 2008529121A JP 2009511426 A5 JP2009511426 A5 JP 2009511426A5
Authority
JP
Japan
Prior art keywords
seq
nos
carrier
acid sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008529121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511426A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/033133 external-priority patent/WO2007027510A2/en
Publication of JP2009511426A publication Critical patent/JP2009511426A/ja
Publication of JP2009511426A5 publication Critical patent/JP2009511426A5/ja
Pending legal-status Critical Current

Links

JP2008529121A 2005-08-30 2006-08-23 ミネラルおよび骨格代謝の調節 Pending JP2009511426A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71315405P 2005-08-30 2005-08-30
US71711505P 2005-09-13 2005-09-13
US80779706P 2006-07-19 2006-07-19
PCT/US2006/033133 WO2007027510A2 (en) 2005-08-30 2006-08-23 Regulation of mineral and skeletal metabolism

Publications (2)

Publication Number Publication Date
JP2009511426A JP2009511426A (ja) 2009-03-19
JP2009511426A5 true JP2009511426A5 (enExample) 2009-07-30

Family

ID=37809379

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008529121A Pending JP2009511426A (ja) 2005-08-30 2006-08-23 ミネラルおよび骨格代謝の調節

Country Status (6)

Country Link
US (6) US20070066514A1 (enExample)
EP (1) EP1937064A4 (enExample)
JP (1) JP2009511426A (enExample)
AU (1) AU2006285127A1 (enExample)
CA (1) CA2621167A1 (enExample)
WO (1) WO2007027510A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101668421B (zh) * 2006-11-16 2014-05-21 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
ES2729051T3 (es) * 2009-07-29 2019-10-30 Kai Pharmaceuticals Inc Agentes terapéuticos para reducir los niveles de hormona paratiroidea
EP2589262B1 (en) * 2010-07-01 2015-08-19 Goji Limited Processing objects by radio frequency (rf) energy
WO2012170955A1 (en) 2011-06-08 2012-12-13 Kai Pharmaceuticals, Inc. Therapeutic agents for regulating serum phosphorus
RU2730997C1 (ru) * 2020-03-10 2020-08-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ диагностики первичного гиперпаратиреоза
RU2730999C1 (ru) * 2020-03-10 2020-08-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ биохимической диагностики первичного гиперпаратиреоза

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384313A (en) * 1993-11-24 1995-01-24 Wisconsin Alumni Research Foundation 21-norvitamin D compounds
ES2281964T3 (es) * 1998-05-18 2007-10-01 University College London Hormona polipeptidica derivada de tumor humano fosfatonina.
US6673900B2 (en) * 1999-11-04 2004-01-06 University College London Polypeptide hormone-phosphatonin
EP1207896A4 (en) * 1999-09-02 2004-09-08 Acologix Inc METHOD AND COMPOSITIONS FOR REDUCING THE SERUM PHOSPHATE MIRROR
US6790639B2 (en) * 2000-02-29 2004-09-14 Pfizer Inc. Mammalian osteoregulins
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US20030175808A1 (en) * 2000-06-21 2003-09-18 Tomofumi Kurokawa Novel protein and dna thereof
US20040048837A1 (en) * 2002-09-06 2004-03-11 Lazarus J. Michael Method for treatment of renal disease
WO2005028504A2 (en) * 2003-09-19 2005-03-31 Board Of Regents, The University Of Texas System Regulation of tissue mineralization and phosphate met abolism by asarm peptides

Similar Documents

Publication Publication Date Title
JP2013507439A5 (enExample)
JP2010534684A5 (enExample)
NZ591497A (en) A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment
JP2004534850A5 (enExample)
RU2600440C3 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
HRP20201353T1 (hr) Agonisti glukagonskog receptora
HRP20140616T1 (hr) Peptidni analog oksintomodulina
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
JP2011526886A5 (enExample)
JP2011528896A5 (enExample)
JP2010503396A5 (enExample)
RU2008136324A (ru) Желудочно-кишечный пролиферативный фактор и его применения
JP2013515057A5 (enExample)
JP2013515055A5 (enExample)
JP2011528895A5 (enExample)
JP2019524836A5 (enExample)
JP2009525052A5 (enExample)
JP2007504269A5 (enExample)
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
JP2005537234A5 (enExample)
WO2008027854A3 (en) Pharmaceutical compositions comprising hgh for oral delivery
JP2007526248A5 (enExample)
JP2013503110A5 (enExample)
WO2011156453A3 (en) Therapeutic peptides
JP2008513510A5 (enExample)